STOCKHOLM, Nov. 30, 2022 /PRNewswire/ BioArctic AB's (publ) (Nasdaq: BIOA B) (Stockholm: BIOA B) partner Eisai announced today that the results from the large global Phase 3 confirmatory
Researchers at Washington University School of Medicine in St. Louis have discovered a biomarker for a rare, deadly brain disease known as corticobasal degeneration (CBD). The biomarker could accelerate efforts to develop treatments for CBD.
Zooming in on a single disease and studying it intensely is often the most productive route to finding treatments. But there's no easy way to distinguish among people living with any of the primary tauopathies -; a group of rare brain diseases marked by rapidly worsening problems with thinking and movement -; because the symptoms are too similar.
Diagnostic marker found for deadly brain disease marked by dementia, movement problems – Washington University School of Medicine in St Louis wustl.edu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wustl.edu Daily Mail and Mail on Sunday newspapers.
Stock Market | FinancialContent Business Page financialcontent.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialcontent.com Daily Mail and Mail on Sunday newspapers.